Prospective monitoring of chronic myeloid leukemia patients from the time of TKI discontinuation: the fate of peripheral blood CD26(+) leukemia stem cells

Introduction: In chronic myeloid leukemia (CML), about half of the patients achieving a deep and stable molecular response with tyrosine kinase inhibitors (TKIs) may discontinue TKI treatment without disease recurrence. As such, treatment-free remission (TFR) has become an ambitious goal of treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Pacelli, Paola, Santoni, Adele, Sicuranza, Anna, Abruzzese, Elisabetta, Giai, Valentina, Crugnola, Monica, Annunziata, Mario, Galimberti, Sara, Iurlo, Alessandra, Luciano, Luigiana, Sorà, Federica, Fava, Carmen, Bestoso, Elena, Marzano, Cristina, Cartocci, Alessandra, Defina, Marzia, Sammartano, Vincenzo, Cencini, Emanuele, Raspadori, Donatella, Bocchia, Monica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10250640/
https://www.ncbi.nlm.nih.gov/pubmed/37305536
http://dx.doi.org/10.3389/fphar.2023.1194712

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10250640/
https://www.ncbi.nlm.nih.gov/pubmed/37305536
http://dx.doi.org/10.3389/fphar.2023.1194712

Ejemplares similares